Biblio

Author Title [ Type

] Year

Filters: Author is Gedde-Dahl, Tobias [Clear All Filters]

Journal Article

Hernández-Boluda JCarlos, Eikema D-J, Koster L, Kröger N, Robin M, de Witte M, Finke J, Finazzi MChiara, Broers A, Raida L, et al. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2023.

B Grønvold L, Ali MMohamed, Myklebust TÅ, Lenartova A, Remberger M, Abrahamsen IWeum, Tjønnfjord GErland, Myhre AEivind, Fløisand Y, Gedde-Dahl T. Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors. EJHaem. 2024;5(1):117-124.

Mellqvist U-H, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase III trial. Blood. 2013.

Moukalled N, Labopin M, Versluis J, Socié G, Blaise D, Salmenniemi U, Rambaldi A, Gedde-Dahl T, Tholouli E, Kröger N, et al. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukem. Am J Hematol. 2024.

Søraas A, Matsuyama M, de Lima M, Wald D, Buechner J, Gedde-Dahl T, Søraas CLund, Chen B, Ferrucci L, Dahl JArne, et al. Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells. Aging Cell. 2019:e12897.

Sanz J, Labopin M, Pabst T, Versluis J, van Gorkom G, Meijer E, Gedde-Dahl T, Montoro J, Arcese W, Pérez-Simón JAntonio, et al. Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party. Bone Marrow Transplant. 2023.

Andersen AMikal, Bergan S, Gedde-Dahl T, Buechner J, Vethe NTore. Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients. J Pharm Biomed Anal. 2021;203:114216.

Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S. Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning. Ther Drug Monit. 2015.

Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.

Cesaro S, Tridello G, Knelange NSimone, Blijlevens N, Martin M, Snowden JA, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T, et al. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. Bone Marrow Transplant. 2021.

Blum S, Chalandon Y, Labopin M, Finke J, Gedde-Dahl T, Ben Othman T, Cornelissen JJ, Jindra P, Labussière-Wallet H, Collin M, et al. Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society. Haematologica. 2024.

Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Reményi P, et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2023.

Jørgensen SF, Buechner J, Myhre AE, Galteland E, Spetalen S, Kulseth MAnn, Sorte HS, Holla ØL, Lundman E, Alme C, et al. A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT. J Clin Immunol. 2021.

Divito SJ, Aasebo AT, Matos TR, Hsieh P-C, Collin M, Elco CP, O'Malley JT, Bækkevold ES, Reims HM, Gedde-Dahl T, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. J Clin Invest. 2020.

Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R-M, Griškevičius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation. Bone Marrow Transplant. 2024.

Federico L, Tvedt THenrik And, Gainullin M, Osen JRøkke, Chaban V, Lund KPersgård, Tietze L, Tran TThe, Lund-Johansen F, Kared H, et al. Robust spike-specific CD4 and CD8 T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study. Front Immunol. 2023;14:1210899.

Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G-N, Blau IWolfgang, Salmenniemi U, Socié G, et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant. 2023.

Tvedt THenrik And, Skaarud KJ, Tjønnfjord GErland, Gedde-Dahl T, Iversen POle, Bruserud Ø. THE SYSTEMIC METABOLIC PROFILE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: EFFECTS OF ADEQUATE ENERGY SUPPORT ADMINISTERED THROUGH ENTERAL FEEDING TUBE. Biol Blood Marrow Transplant. 2019.

Vethe NTore, Andersen AMikal, Gedde-Dahl T, Büchner J, Bergan S. Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor. Ther Drug Monit. 2024.

Hamed RAl, Ngoya M, Galimard J-E, Sengeloev H, Gedde-Dahl T, Kulagin A, Platzbecker U, Yakoub-Agha I, Byrne JL, Valerius T, et al. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study. Cancer. 2023.

Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EMaria, Versluis J, Schroeder T, Blau IWolfgang, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.